Please Wait...

Barbara Clendenen

Main profile

Barbara Clendenen, MBA
Barbara Clendenen, MBA
Director, Business Development, Drug Safety and Regulatory

Barbara Clendenen, MBA, designs Pharmacovigilance and Regulatory solutions that increase compliance and reduce risk for life science organizations. She has over 20 years of experience blending both science and business expertise to assist pharmaceutical, biotech, medical device, and CRO clients in meeting research and post marketing goals. She began her career as a research scientist in Immunology and Oncology.  Since 1998, she has held pivotal roles in business development and sales management within the scientific and clinical research industry for Becton Dickinson, Fisher Scientific, and Bio-Rad. Prior to joining Bioclinica in 2015, she led the Business Development Team at Quorum Review IRB, developed the organization's entry into the hospital and AMC market, and participated in CIRB (Consortium of Independent Review Boards). Barbara graduated from University of Washington with a Bachelor's degree in Microbiology and from Seattle University with a Master's in Business Administration.

Blogs

The electronic common technical document (eCTD) is an interface for the pharmaceutical industry to transfer regulatory information based on the Common Technical Document (CTD) format, which is an agreed common format for applications that will be acceptable in all three ICH-Regions (US, EU & Japan) and other countries.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @Xtalks: Removing Risk from #ClinicalTrial Management System (CTMS) Implementations @bioclinica https://t.co/EfuSVMSL13
bioclinica (5 hours ago)
Our Research Dev. Director Marieke Cajal in a poster presentation at #CNS Summit showed, "How to Scale up Recruitme… https://t.co/ySQpGIjvt9
bioclinica (5 hours ago)
Great advice on imaging in #clinicaltrials! https://t.co/adsP8h99Ic
bioclinica (3 days ago)
https://t.co/UZQTot9ovJ
bioclinica (3 days ago)
RT @Xtalks: When is Central Imaging Needed in #ClinicalTrials? @bioclinica https://t.co/fYGvqU46TI
bioclinica (3 days ago)
RT @phillytechnews: 11/7: BioClinica, USA Technologies buy California firms ; First Round names female general partner https://t.co/MAvm6…
bioclinica (3 days ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices